1. Home
  2. SFST vs IMMP Comparison

SFST vs IMMP Comparison

Compare SFST & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern First Bancshares Inc.

SFST

Southern First Bancshares Inc.

HOLD

Current Price

$52.40

Market Cap

421.9M

Sector

Finance

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.45

Market Cap

410.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFST
IMMP
Founded
1999
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.9M
410.7M
IPO Year
2012
2012

Fundamental Metrics

Financial Performance
Metric
SFST
IMMP
Price
$52.40
$0.45
Analyst Decision
Buy
Hold
Analyst Count
1
3
Target Price
$64.00
$5.50
AVG Volume (30 Days)
73.7K
2.4M
Earning Date
04-23-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
94.76
N/A
EPS
3.72
N/A
Revenue
$6,282,000.00
N/A
Revenue This Year
$10.47
$382.75
Revenue Next Year
$12.19
N/A
P/E Ratio
$13.90
N/A
Revenue Growth
12.99
N/A
52 Week Low
$29.80
$0.46
52 Week High
$62.00
$3.53

Technical Indicators

Market Signals
Indicator
SFST
IMMP
Relative Strength Index (RSI) 38.35 13.43
Support Level $50.27 N/A
Resistance Level $52.60 $1.90
Average True Range (ATR) 2.10 0.12
MACD -0.58 -0.23
Stochastic Oscillator 16.77 0.54

Price Performance

Historical Comparison
SFST
IMMP

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: